Phenotypic analysis of antigen-specific T lymphocytes

Science

Volumn 274, Issue 5284, 1996, Pages 94-96

  Altman, John D ^a   Moss, Paul A H ^b   Goulder, Philip J R ^b   Barouch, Dan H ^b   McHeyzer Williams, Michael G ^a   Bell, John I ^b   McMichael, Andrew J ^b   Davis, Mark M ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; TETRAMER;

ANTIGEN SPECIFICITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFLUENZA VIRUS A; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, VIRAL; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; COLORING AGENTS; EPITOPES; FLOW CYTOMETRY; GENE PRODUCTS, GAG; HIV SEROPOSITIVITY; HLA-A2 ANTIGEN; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHENOTYPE; RNA-DIRECTED DNA POLYMERASE; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029743737     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.274.5284.94     Document Type: Article

References (41)

1. M. G. McHeyzer-Williams and M. M. Davis, Science 268, 106 (1995).
2. L. K. Selin, K. Vergilis, R. M. Welsh, S. R. Nahill, J. Exp. Med. 183, 2489 (1996).
3. P. C. Doherty, D. J. Topham, R. A. Tripp, Immunol. Rev. 150, 23 (1996).
4. F. M. Gotch, D. F. Nixon, N. Alp, A. J. McMichael, L. K. Borysiewicz, Int. Immunol. 2, 707 (1990).
5. P. A. Moss et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5773 (1995).
6. G. Pantaleo, S. Koenig, M. Baseler, H. C. Lane, A. S. Fauci, J. Immunol. 144, 1696 (1990).
7. M. H. Julius, T. Masuda, L. A. Herzenberg, Proc. Natl. Acad. Sci. U.S.A. 69, 1934 (1972); K. Hayakawa, R. Ishii, K. Yamasaki, T. Kishimoto, R. R. Hardy, ibid. 84, 1379 (1987); M. G. McHeyzer-Williams, G. J. Nossal, P. A. Lalor, Nature 350, 502 (1991).
8. M. H. Julius, T. Masuda, L. A. Herzenberg, Proc. Natl. Acad. Sci. U.S.A. 69, 1934 (1972); K. Hayakawa, R. Ishii, K. Yamasaki, T. Kishimoto, R. R. Hardy, ibid. 84, 1379 (1987); M. G. McHeyzer-Williams, G. J. Nossal, P. A. Lalor, Nature 350, 502 (1991).
9. M. H. Julius, T. Masuda, L. A. Herzenberg, Proc. Natl. Acad. Sci. U.S.A. 69, 1934 (1972); K. Hayakawa, R. Ishii, K. Yamasaki, T. Kishimoto, R. R. Hardy, ibid. 84, 1379 (1987); M. G. McHeyzer-Williams, G. J. Nossal, P. A. Lalor, Nature 350, 502 (1991).
10. H. R. MacDonald, J. L. Casanova, J. L. Maryanski, J. C. Cerottini, J. Exp. Med. 177, 1487 (1993); P. R. Walker, T. Ohteki, J. A. Lopez, H. R. MacDonald, J. L. Maryanski, J. Immunol. 155, 3443 (1995); S. L. Reiner, Z.-E. Wang, F. Hatam, P. Scott, R. M. Locksley, Science 259, 1457 (1993).
11. H. R. MacDonald, J. L. Casanova, J. L. Maryanski, J. C. Cerottini, J. Exp. Med. 177, 1487 (1993); P. R. Walker, T. Ohteki, J. A. Lopez, H. R. MacDonald, J. L. Maryanski, J. Immunol. 155, 3443 (1995); S. L. Reiner, Z.-E. Wang, F. Hatam, P. Scott, R. M. Locksley, Science 259, 1457 (1993).
12. H. R. MacDonald, J. L. Casanova, J. L. Maryanski, J. C. Cerottini, J. Exp. Med. 177, 1487 (1993); P. R. Walker, T. Ohteki, J. A. Lopez, H. R. MacDonald, J. L. Maryanski, J. Immunol. 155, 3443 (1995); S. L. Reiner, Z.-E. Wang, F. Hatam, P. Scott, R. M. Locksley, Science 259, 1457 (1993).
13. M. Corr et al., Science 265, 946 (1994); K. Matsui, J. J. Boniface, P. Steffner, P. A. Reay, M. M. Davis, Proc. Natl. Acad. Sci. U.S.A. 91, 12862 (1994); Y. Sykulev et al., Immunity 1, 15 (1994).
14. M. Corr et al., Science 265, 946 (1994); K. Matsui, J. J. Boniface, P. Steffner, P. A. Reay, M. M. Davis, Proc. Natl. Acad. Sci. U.S.A. 91, 12862 (1994); Y. Sykulev et al., Immunity 1, 15 (1994).
15. M. Corr et al., Science 265, 946 (1994); K. Matsui, J. J. Boniface, P. Steffner, P. A. Reay, M. M. Davis, Proc. Natl. Acad. Sci. U.S.A. 91, 12862 (1994); Y. Sykulev et al., Immunity 1, 15 (1994).
16. P. J. Schatz, Biotechnology 11, 1138 (1993).
17. D. N. Garboczi, D. T. Hung, D. C. Wiley, Proc. Natl. Acad. Sci. U.S.A. 89, 3429 (1992).
18. 2, 5 mM. BirA was produced from the overexpression plasmid pJS169 in Escherichia coli BL21 and purified on Blue Sepharose, followed by ion exchange on S Sepharose Fast Flow (P. Schatz and R. Armstrong, personal communication). Biotinylation levels were usually between 70 and 100%. HLA-A2 tetramers were prepared by mixing the biotinylated protein with phycoerythrin-labeled UltraAvidin (Leinco) at a molar ratio of 4:1. Tetramers were purified by gel filtration on a Superdex S-200 column (Pharmacia).
19. Our attempts to produce effective avidin-based staining reagents from randomly biotinylated MHC molecules were unsuccessful, though this approach has succeeded in other systems [C. R. Parish, M. A. Reeny, M. H. Knoppers, J. C. Waldron, H. S. Warren, J. Immunol. 150, 4833 (1993)].
20. R. P. Johnson et al., ibid. 147, 1512 (1991).
21. B. D. Walker et al., Science 240, 64 (1988).
22. T. J. Tsomides, B. D. Walker, H. N. Eisen, Proc. Natl. Acad. Sci. U.S.A. 88, 11276 (1991).
23. Viral peptide-specific CTLs were generated as described (20, 30). Briefly, peripheral blood mononuclear cells were separated from whole blood and restimulated with autologous phytohemagglutinin lymphoblasts. Cells were cultured in RPMI 164C (Gibco) with 10% fetal calf serum (R10) and antibiotics for 1 week, and subsequently with R10 and 10% Lymphocult T (Biotest) added. Viral peptide-specific lines were generated and maintained from the bulk culture by use of peptide-pulsed irradiated autologous B-lymphoblastoid cells weekly as feeders. The HLA-A2-Pol-specific clone 20 was cloned by LDA techniques.
24. For staining, approximately 200,000 CTLs were incubated at 4°C for 1 hour with saturating concentrations of CyChrome-conjugated antibody to CD8α (clone RPA-T8, Pharmingen) and phycoerythrin-labeled HLA-A2-peptide tetramers at a concentration of HLA-A2 of approximately 0.5 mg/ml total in PBS plus 2% fetal calf serum plus 5 mM sodium azide. After washing, the cells were fixed in PBS plus 2% formaldehyde. We then analyzed the cells on a FAC-Scan (BDIS), using CELL Quest software.
25. Peptide-specific lines were assayed 4 to 5 days after restimulation. Standard 4-hour chromium-51 release assays were performed with autologous chromium-51-labeled B-lymphoblastoid cells as targets. Background chromium release was less than 20%. Percent lys's was calculated from the formula 100 × (E - M)/(T - M), where E is the experimental release, M the release in the presence of R10 media alone, and T the release in the presence of 5% Triton X-100 detergent.
26. P. J. Lehner et al., J. Exp. Med. 181, 79 (1995).
27. A. Hoffenbach et al., J. Immunol. 142, 452 (1989); A. Carmichael, X. Jin, P. Sisscns, L. Borysiewicz, J. Exp. Med. 177, 249 (1993); R. A. Koup et al., ibid. 174, 1593 (1991).
28. A. Hoffenbach et al., J. Immunol. 142, 452 (1989); A. Carmichael, X. Jin, P. Sisscns, L. Borysiewicz, J. Exp. Med. 177, 249 (1993); R. A. Koup et al., ibid. 174, 1593 (1991).
29. A. Hoffenbach et al., J. Immunol. 142, 452 (1989); A. Carmichael, X. Jin, P. Sisscns, L. Borysiewicz, J. Exp. Med. 177, 249 (1993); R. A. Koup et al., ibid. 174, 1593 (1991).
30. M. Roederer and A. Landay, in The Handbook of Experimental Immunology, vol. 4, L. A. Herzenberg, L. A. Herzenberg, C. Blackwell, D. Weir, Eds. (Blackwell, Cambridge, MA, ed. 5, in press).
31. C. Zimmerman, K. Brduscha-Riem, C. Blaser, R. M. Zinkernagel, H. Pircher, J. Exp. Med. 183, 1367 (1996).
32. L. Bruno, J. Kirberg, H. von Boehmer, Immunity 2, 37 (1995).
33. S. Hou and P. C. Doherty, J. Immunol. 150, 5494 (1993); R. A. Tripp, S. Hou, P. C. Doherty, ibid. 154. 5870 (1995); C. Ewing, D. J. Topham, P.C. Doherty, Virology 210, 179 (1995).
34. S. Hou and P. C. Doherty, J. Immunol. 150, 5494 (1993); R. A. Tripp, S. Hou, P. C. Doherty, ibid. 154. 5870 (1995); C. Ewing, D. J. Topham, P.C. Doherty, Virology 210, 179 (1995).
35. S. Hou and P. C. Doherty, J. Immunol. 150, 5494 (1993); R. A. Tripp, S. Hou, P. C. Doherty, ibid. 154. 5870 (1995); C. Ewing, D. J. Topham, P.C. Doherty, Virology 210, 179 (1995).
36. H. S. Ko, S. M. Fu, R. J. Winchester, D. T. Yu, H. G. Kunkel, J. Exp. Med. 150, 246 (1979).
37. W. Holter, O. Majdic, K. Liszka, H. Stockinger, W. Knapp, Cell. Immunol. 90, 322 (1985).
38. J. D. Altman et al., data not shown.
39. Abbreviations for the amino acid residues are: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His: I, Ile; K, Lys; L1 Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
40. D. F. Nixon et al., Nature 336, 484 (1988).
41. β assignment of clone 20; R. Boone for assistance with the flow cytometer; and L. Ngyuen for technical assistance. We also thank P. Schatz for the BirA enzyme and expression plasmid, and D. Garboczi and D. Wiley for the gift of the HLA-A2 expression plasmid. J.D.A. received funding from an American Cancer Society postdoctoral fellowship, and P.A.H.M. is a Medical Research Council Clinician Scientist. M.G.M. was a fellow of the Lucille P. Markey Charitable Trust, D.H.B. was a Marshall Scholar, and P.J.R.G. is a Medical Research Council training fellow. We also acknowledge NIH for support of M.M.D., and the Medical Research Council and the Wellcome Trust for support of A.J.M. and J.I.B.